ENO Breathe vs Usual Care in COVID-19 Recovery
Launched by IMPERIAL COLLEGE LONDON · Mar 31, 2021
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
ENO Breathe is a breathing and wellbeing programme developed specifically for people recovering from COVID-19, who are still suffering from breathlessness and associated anxiety. Delivered by ENO in collaboration with Imperial College Healthcare teams entirely online, the programme focuses on breathing re-training through singing. Initial evaluation of the project suggested health improvements related to participation, however, a properly conducted efficacy study is needed.
DESIGN: An assessor blind, parallel group, randomised controlled trial, to assess the effects of ENO Bre...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults recovering from COVID-19 with ongoing breathlessness and/or anxiety.
- • Referred from a specialist COVID-19 clinics aligned with the project, after appropriate clinical evaluation and investigation
- • Internet access with appropriate device (e.g. computer or tablet)
- Exclusion Criteria:
- • - Unable to participate due to comorbidity (e.g. life limiting illness, cognitive impairment)
About Imperial College London
Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Nicholas S Hopkinson
Principal Investigator
Imperial College London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials